People with HIV in Europe and Australia who switch to injectable treatment with cabotegravir/rilpivirine are just as likely to stay on their new regimen and maintain viral suppression as people taking oral treatment containing dolutegravir or bictegravir, a large international cohort study reported at HIV Glasgow 2026.
The findings come from one of the largest cohort studies to report on real-world use of the injectable regimen.
Previous cohort studies that reported on real-world use of cabotegravir/rilpivirine were either confined to one clinical centre or country, or lacked a comparator group.
Source : aidsmap
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.